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Abstract. despite improvements in therapy and management, 
cancer represents and remains a major cause of mortality and 
morbidity worldwide. Although genetics serve an important 
role in tumorigenesis and tumour progression, the tumour 
microenvironment (TME) in solid tumours is also impor-
tant and has been indicated to contribute to these processes. 
Stromal cell-derived factors (SdFs) represent an important 
family within the TME. The family includes SdF-1, SdF-2, 
SdF2-like 1 (SdF2L1), SdF-3, SdF-4 and SdF-5. SdF-1 has 
been demonstrated to act as a positive regulator in a number 
of types of tumour, such as oesophago-gastric, pancreatic, 
lung, breast, colorectal and ovarian cancer, while the biology 
and functions of other members of the SdF family, including 
SdF-2, SdF2L1, SdF-4 and SdF-5, in cancer are different, 
complex and controversial, and remain mainly unknown. Full 
identification and understanding of the SDFs across multiple 
types of cancer is required to elucidate their function and 
establish potential key targets in cancer.
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1. Introduction
The number of people diagnosed with cancer worldwide has 
consistently increased in recent years. There were >18 million 
new patients diagnosed with cancer and 9 million deaths 
caused by cancer according to 2018 GLOBOcAN (1).
Interactions between stromal, epithelial and extracellular 
matrix (EcM) components are increasingly recognized as 
being important in cancer development and progression (2). 
Stromal cells, together with EcM components, make up the 
tumour microenvironment (TME), which is vital for cancer 
cell proliferation, invasion and metastatic progression (2). 
Stromal cell-derived factors (SdFs) comprise a group of 
proteins derived from stromal cells (3). The family mainly 
includes SdF-1, SdF-2, SdF2-like 1 (SdF2L1), SdF-3, SdF-4 
and SDF‑5. These factors have all been identified in human 
cancer tissues except for SdF-3, which has been found to be 
present only in murine samples (3) (Table I). Although they 
are named similarly and belong to the same group, they exhibit 
different structures and functions in cancer (3). SdF-1 has 
been the most studied factor in this group, while less is known 
about the other factors and their association with cancer.
2. Role of SDF‑1 in promoting cancer
SdF-1, a 68-amino acid protein, belongs to the chemokine 
family (4). chemokines are a large family that can regulate stem 
or progenitor cell proliferation and movement (5). chemokines 
have been classified into four main subfamilies: cXc, cc, 
c3Xc and Xc, depending on the presence and number of amino 
acids between N-terminal cysteine residues (6). SdF-1 belongs 
to the cXc chemokine family and it is also known as cXc motif 
ligand 12 (cXcL12). It is expressed in various types of cancer, 
including oesophago-gastric, pancreatic, lung, breast, colorectal 
and ovarian cancer (7). As a receptor of cXcL12, cXc motif 
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chemokine receptor 4 (cXcR4) has been found to be overex-
pressed in >30 types of malignant tumours (7), such as lung (4), 
breast (8) and intestinal cancer (9). There is increasing evidence 
demonstrating that cXcL12, as a secreted factor in the TME, 
enhances tumour growth and survival (10,11), adhesion (12,13), 
chemoresistance (4), immunotherapy resistance (14-16), migra-
tion and invasion (9,17-19), angiogenesis and metastasis (20) 
via the cXcL12/cXcR4 axis (20,21), mainly in lung cancer, 
breast cancer, gastric cancer, colon cancer, pancreatic cancer, 
ovarian carcinoma, cervical carcinoma, endometrial cancer and 
leukaemia (8,13,22-25). The JAK2/STAT3, MAPK, PI3K/AKT 
and PI3K/Pyk2 signalling pathways have been identified as 
acting downstream of the cXcL12/cXcR4 axis (4,17). As 
aforementioned, the connection between cXcL12 and cXcR4 
contributes to malignant behaviour. Therefore, targeting the 
cXcL12/cXcR4 axis may be a viable target for tumour treat-
ment. cTcE-9908, a cXcL12 analogue, has been proven to 
inhibit osteosarcoma growth, adhesion and metastasis (26), 
as well as breast cancer cell proliferation (27). Plerixafor 
(AMd3100), as a cXcR4 inhibitor, competitively inhibits 
prostate tumorigenesis in the bone (28), decreases ovarian 
cancer growth and metastasis (29), prevents brain-specific 
metastasis (30) and protects the blood-brain barrier in patients 
with lung cancer (30).
It is well known that genetic polymorphisms serve a 
vital role in cancer pathogenesis. A meta-analysis including 
17,876 participants concluded the association between SdF-1 
rs1801157 polymorphism and cancer risk, demonstrating that 
the SdF-1 rs1801157 polymorphism may serve as a risk factor 
for lung and urologic cancer (31).
The function of SdF-1 has been widely investigated in 
cancer; however, the functions of the other stromal derived 
factors, SdF-2, SdF2L1, SdF-4 and SdF-5, are less known 
in cancer. Although they are named similarly and belong to 
the same family, they exhibit distinct structures and functions.
3. Role of SDF‑2 and SDF2L1 in endoplasmic reticulum 
(ER) stress and cancer
SdF-2 is a small protein of 211 amino acids, consisting of 
protein (O-mannosyltransferase, inositol 1, 4, 5-triphosphate 
receptor and ryanodine receptor) domains, which are known as 
MIR motifs (32). Since SdF-2 lacks a hydrophobic region in 
addition to that at the N terminus, it was initially thought that 
SdF-2 may be a secretory, but not membranous protein (33). 
The SdF-2 gene is located on human chromosome 17 at qll.2, as 
identified using in situ hybridization, and on chromosome 11 in 
mice (33). SdF-2 is ubiquitously expressed in lung, breast, colon, 
liver and kidney (3,33,34). SdF-2 in humans and mice contains 
a tetrapeptide at its c-terminus similar to the KdEL motif (a 
c-terminal sequence consisting of Lys-Asp-Glu-Leu), which 
characterises ER resident proteins (35). SdF2L1 is a homologue 
of SdF-2; it is an ER stress-inducible gene and a member of 
the O-mannosyltransferase protein family (35). Mouse SdF2L1 
and SdF-2 sequences are 78% similar and 68% identical (36). 
SdF2L1 contains a c-terminal HdEL sequence, which is an ER 
retention-like motif that acts as an ER localisation signal (35). 
Both proteins are ER residents, but SdF-2 is constitutively 
expressed, whereas SdF2L1 expression is induced by ER 
stress (36). Since the ER is the appropriate environment for protein 
folding, secretion and quality control, ER impairment can lead 
to the accumulation of unfolded proteins, a phenomenon known 
as ER stress, activating the unfolded protein response (UPR) 
pathway (37). chronic ER stress can be triggered by a number 
of human diseases, such as cancer, diabetes and neurodegenera-
tive disorders (38). Similarly, an adverse cellular environment, 
including low nutrient levels, low pH, oxygen deprivation and 
gene mutation, can also lead to ER stress (36). The UPR process 
acts to maintain cellular functions and sustain homeostasis, or 
to activate apoptosis, acting as quality control (36). The UPR 
process, together with other homeostatic regulatory systems, 
helps to minimise the disturbances in the environment (36). 
Schott et al (39) demonstrated that SdF2-like proteins are 
induced by ER-stress causing the accumulation of unfolded 
proteins and that they served a functional role in ER-stress, as 
well as in the UPR pathway. Additionally, it has been observed 
that following ER stress and the activation of the UPR pathway, 
SdF2-like proteins were increased, while silencing SdF2-like 
proteins led to an imbalance in the cellular environment (35). 
Therefore, SdF2L1 is suggested to be a critical protein in ER 
stress. A further understanding of the mechanisms of SdF2L1 
on ER stress may be helpful in identifying its possible down-
stream targets in cancer (37).
There is some direct evidence that has given insight into 
the impact of SdF-2 and SdF2L1 in cancer. Kang et al (3) 
demonstrated that SdF-2 and SdF2L1 displayed differ-
ential expression patterns in patients with breast cancer. 
Upregulation of these factors was associated with a better 
clinical outcome, which is markedly different from SdF-1 (3). 
SDF‑2 transcript levels were significantly lower in patients 
with metastasis (0.0014±0.0001) and in those who died of the 
disease (0.049±0.037) (3). Furthermore, using the Nottingham 
Prognostic Index as a prognostic factor led to the same 
outcome that lower transcript levels were associated with 
a poor prognosis (3). Similar to SdF-2, the transcript levels 
of SdF2L1 were also lower in patients with a poor prog-
nosis (0.012±0.008) than in patients with a good prognosis 
(0.529±0.50) (3). Moreover, the levels of SdF2L1 in patients 
with metastatic disease and in those who had died from cancer 
were markedly lower than in patients who were disease-free, 
and the group with the highest tumour grade exhibited the 
lowest transcript levels of SdF2L1 (3). Overall, this suggested 
that lower levels of SdF-2 and SdF2L1 indicated a poor prog-
nosis (3). considering the various ‘omic’ technologies that have 
expanded the expectations for biomarkers in the cancer field, 
Vendrell et al (34) analysed genomics and transcriptomics 
data in a series of R0 dukes B and dukes c colorectal carci-
nomas to evaluate the identification of outcome predictors; the 
multivariate cox model was used to identify 68 genes associ-
ated with disease-free survival. consequently, 74% of these 
genes were upregulated (34). In the transcriptomic analyses, 
downregulation of SdF-2 expression was associated with a 
poor prognosis (P<0.01) (34). Lower SdF-2 expression was 
observed to be an indicator of shorter disease-free survival in 
colorectal cancer (34). In order to discover potential predic-
tive biomarkers, Willis et al (40) performed a meta-analysis; 
the results of the meta‑analysis were statistically significant 
with a false discovery rate <0.05. The results revealed that 
low SdF2L1 mRNA expression was associated with a poor 
prognosis in patients with ovarian serous carcinoma (40).
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However, other studies have demonstrated the opposite 
results. For example, Giulianelli et al (41) demonstrated that 
SdF-2 was highly expressed in the hormone-independent 
tumour stroma compared with in the hormone-dependent 
tumour stroma from a medroxyprogesterone acetate-induced 
mouse breast cancer model. The aforementioned study 
supported the hypothesis that SdF-2 may be involved with 
hormone-independent tumour growth (41). Furthermore, 
Takahashi et al (42) revealed that SdF-2 expression was 
upregulated in oxaliplatin (OXA)-resistant gastric cancer cells 
and identified SDF‑2 as a heat shock protein 72 (hsp72) client 
protein, which is unique to OcUM-2M/OXA cells. Hsp72 
is a well-known stress-induced molecule that assists in the 
folding of nascent polypeptides and the refolding of denatured 
proteins; its constitutive overexpression enhances cancer cell 
stress tolerance and enables the cancer cell to adapt to harsh 
conditions (42). Hsp72 binds to the SdF-2 protein to promote 
refolding and prevents SdF-2 degradation (42). The data from 
the aforementioned study demonstrated that suppression of 
SdF-2 results in enhanced OXA-induced anti-proliferative 
effects and apoptosis (42). The data suggested that SdF-2 may 
be a novel therapeutic target in the treatment of OXA-resistant 
gastric cancer cells (42). Nevertheless, to the best of our knowl-
edge there is currently no molecule that has been developed 
to target SdF-2 for cancer treatment. SdF-2 may potentially 
provide an interesting target for tumour therapies and as a 
prognostic factor in the future, but further studies are required.
4. Role of SDF‑4 in cancer cell mobility, proliferation and 
migration
The SdF-4 protein is a ca2+-binding protein of 45 kda (cab45), 
and a member of the cab45/reticulocalbin/ERc45/calumenin 
protein family (43). It is associated with ca2+-dependent secre-
tory pathways and involved in multiple diseases, including 
cancer (44). It consists of 361 amino acids and the corre-
sponding gene has seven exons (45). It is located on the 1p36.33 
chromosome (44). cab45 has a signal sequence, six EF-hands 
and a HEEF motif at the c-terminal (43,46). Alternative 
splicing produces three isoforms with different physiological 
and pathophysiological characters, namely the Golgi-localised 
variant (cab45-G), the cytosolic variant (cab45-c) and the 
secreted variant (cab45-S) (47). cab45-G is named according 
to its main localisation to the Golgi complex (44). cab45-c 
is nearly identical to the 130 amino acids of cab45-G, except 
that cab45-c lacks the signal sequence and is localised in the 
cytosol (48). cab45-c has neither a sixth-EF-hand nor a HEEF 
sequence, and it participates in the exocytosis of zymogen 
granules (48). cab45-S is located in the ER, is secreted and 
differs from cab45-G at the c-terminal sequences with no 
sixth EF-hand or HEEF motif (44).
cab45 has been implicated to serve a role in numerous 
diseases, including cancer, where it is involved in cell 
migration and proliferation through a number of molecular 
mechanisms (44). cab45 upregulation has been suggested 
in Panc1 pancreatic cancer cells (49), LIM1215 colon cancer 
cells (50), HeLa cervical cancer cells (44) and oesophageal 
cancer cells (51), suggesting that cab45 may be involved in 
cancer progression. cancer cell mobility is a vital feature in 
the process of invasion and migration (52). In order to promote 
migration and invasion, factors are secreted into the environ-
ment to provide proteins to the leading edge of a cell, which 
can pull the cell forward (53). The polarized orientation of 
the Golgi complex towards the leading edge of a migrating 
cell is important to ensure that factors required for persistent 
migratory activity are secreted at the cell's leading edge (54). 
It has been reported that after inhibiting vesicle formation 
at the trans-Golgi Network (TGN), the resultant blocking of 
secretion disturbs membrane delivery to the leading edge and 
directional cell migration (55). cab45 has been proposed to 
serve a pivotal role in secretion at the Golgi complex (44). 
Hence, cab45 may serve a potential role in tumour cell 
mobility (56).
cab45 has also been implicated in cancer cell prolif-
eration. A previous study revealed that cab45 expression 
was significantly higher in pancreatic cancer cells compared 
with in non-neoplastic ductal cells using the stable isotope 
labelling with amino acids method (48). Additionally, 
Grønborg et al (49) confirmed the upregulation of Cab45 in 
pancreatic cancer cells, in contrast to non-neoplastic ductal 
cells, by immunohistochemical labelling, and indicated that 
cab45 may be a potential biomarker in pancreatic tumours. 
Luo et al (44) arrived to a similar conclusion, revealing that 
there was high cab45-G expression in the HeLa cervical cancer 
cell line. The aforementioned findings are in accordance with 
the finding that Cab45‑S regulates the Ca2+ level of the ER 
by binding to sarco/ER ca2+-ATPase 2b and acts as a crucial 
regulator of proliferation in cervical cancer cell lines (47). It is 
Table I. SdFs expression in different types of tumour.
SdFs Types of tumour (Refs.)
SdF-1 Oesophago-gastric, pancreatic, lung, breast, colorectal and ovarian cancer (7)
SdF-2 Breast cancer (3), colorectal carcinoma (34), hormone-independent tumour from a medroxyprogesterone 
 acetate mouse breast cancer model (41) and oxaliplatin-resistant gastric cancer cells (42)
SdF2L1 Breast cancer (3) and ovarian serous carcinoma (40)
SdF-4 Pancreatic cancer (48,49), cervical cancer HeLa cell line (44) and breast cancer (44)
SFRP2 Lung cancer cells (66), choriocarcinoma (67), gastric cancer (68), prostate cancer (69), melanoma (71,79), 
 colorectal cancer (74), liver cancer (73) and breast cancer (78)
SdF, stromal cell-derived factor; SdF2L1, SdF2-like 1; SFRP2, secreted frizzled-related protein 2.
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well known that ca2+ serves a vital role in cellular prolifera-
tion. cab45-S can lead to nuclear translocation of the nuclear 
factor of activated T cells (NFAT) by increasing ca2+ levels 
that result in cell proliferation (47) (Fig. 1). Intracellular 
levels of ca2+ are limited, with prolonged bouts of signalling 
dependent on the influx of external Ca2+ via the store oper-
ated ca2+ channels (SOcs) in the plasma membrane (50). 
Weiss et al (57) demonstrated that the anti-proliferative 
effect of non‑steroidal anti‑inflammatory drugs (NSAIDs) in 
colorectal cancer (cRc) cells was enhanced when the entry of 
SOcs was inhibited. Additionally, Ji et al (50) revealed that, 
using difference gel electrophoresis analysis, when the cRc 
LIM1215 cell line was treated with sulindac, a type of NSAId, 
Cab45 was secreted. A similar conclusion was confirmed by 
western blot analysis in other cRc cell lines, such as HcT116, 
SW480 and SW1463 (50). Therefore, it may be hypothesised 
that cab45 may participate in SOcs entry to regulate the 
effect of NSAIds on cRc cells and that cab45 upregulation 
may be associated with tumour cell proliferation.
Finally, cab45-G was found to promote cell migration and 
metastasis. The process of tumour migration and metastasis is 
complex and involves numerous biological aspects, including 
the effect of epithelial-mesenchymal transition (EMT), matrix 
metalloproteinases (MMPs) and EcM proteins. EMT is a crit-
ical process in epithelial cells, allowing them to attain migratory 
and diffusive abilities (58). during EMT, epithelial cells lose 
cell-to-cell junctions and apico-basal polarity, and develop an 
enhanced migratory capacity and upregulate N-cadherin and 
β-catenin expression, which then leads to tumour cell migra-
tion (53). Firstly, cab45 contributes to the enhanced expression 
levels of EMT-associated proteins, including N-cadherin, 
β-catenin and vimentin, in breast cancer, while the levels of 
E-cadherin are decreased (44). In addition, cab45-G has been 
associated with MMPs in human cervical cancer tissues (44). 
MMPs contribute to the cleavage of the matrisome (global 
composition of the EcM proteome) and of proteins that are 
responsible for EcM remodelling, causing EcM degrada-
tion (59). Additionally, MMPs activate some bioactive molecules, 
including cytokines, growth factors and receptors, which have 
been proved to promote tumour progression and metastasis (60). 
Cab45‑G was demonstrated to be significantly associated with 
MMP2 expression, which has been implicated in tumour 
metastasis by activating the ERK signalling pathway in HeLa 
cells (44) (Fig. 1). Similar findings have revealed that Cab45 is 
responsible for successful sorting of a subset of proteins at the 
TGN for cell migration, such as the EcM-associated proteins 
matrix Gla protein, thrombospondins 1 and 3, and MMP2 (56). 
Therefore, the aforementioned studies suggest that cab45-G 
may regulate cell migration through EcM-associated proteins, 
MMPs and molecular mediators of EMT (44,56,58,60).
Overall, cab45 may serve as a therapeutic target for cancer 
treatment and a potential predictor. However, to the best of 
our knowledge, no studies have been performed to explore the 
corresponding targeted therapy to cab45.
5. Controversial roles of SFRP2 in the Wnt/β‑catenin 
signalling pathway and methylation of SFRP2 in cancer
SdF-5 was initially discovered from a cdNA library from 
a murine bone marrow stromal cell line (61). Kang et al (3) 
Figure 1. Function of cab45-S in the ER and cab45-G in the Golgi apparatus. In the ER, cab45-S binding to SERcA2b leads to extracellular ca2+ entry, 
which activates ca2+-NFAT signalling. This causes NFAT translocation to the nucleus, resulting in cell proliferation. cab45-G enhances cancer metastasis by 
increasing MMP2 expression via the ERK signalling pathway (44,47). The figure was prepared utilising templates obtained from www.proteinlounge.com. 
ER, endoplasmic reticulum; SERcA2b, sarco/ER ca2+-ATPase 2b; NFAT, nuclear factor of activated T cells; cab, ca2+-binding protein; S, secreted variant; 
G, Golgi-localised variant; MMP2, matrix metalloproteinase 2.
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reported that SdF-5 transcripts were decreased in breast 
cancer, but little knowledge is available with regard to SdF-5 
function. SdF-5 belongs to the secreted frizzled proteins and it 
is similar to secreted frizzled-related protein 2 (SFRP2) (36). 
SFRP2 was identified as a member of the SFRP family (62). 
SdF-5 is homologous to Frizzled, which is the extracellular 
portion of the Wnt receptor (62), and so is able to compete with 
Frizzled receptors in interactions with Wnt proteins (63).
Wnt/β-catenin signalling serves a key role in various 
biological processes including carcinogenesis, embryonic 
development and neurodegenerative diseases (62). It is highly 
recognised that Wnt/β-catenin signalling is activated in 
various types of human cancer, including non-small cell lung 
cancer (NScLc), melanoma and colorectal cancer. When the 
Wnt ligand binds to the Frizzled/lipoprotein receptor-related 
protein 5/6, the Wnt/β-catenin signalling pathway is activated 
and dishevelled 3 simultaneously starts to accumulate, which 
inhibits the combination of β-catenin, Axin, adenomatosis 
polyposis coli and glycogen synthase kinase-3β; this in turn 
suppresses phosphorylation and degradation of β-catenin (63). 
consequently, the increased accumulation of β-catenin in the 
cytoplasm results in its translocation to the nucleus, where it 
interacts with members of the T-cell factor/lymphoid enhancer 
factor family of transcription factors to stimulate the expres-
sion of genes involved in cell survival, proliferation and 
osteoblastic differentiation (63,64) (Fig. 2A).
Increasing evidence has demonstrated that SFRP2 can 
regulate Wnt/β-catenin signalling in tumours, acting as 
an antagonist and contributing to the inhibition of tumour 
malignancy (65). SFRP2 expression is downregulated in the 
NScLc A549 cell line compared with in a normal pulmonary 
epithelial cell line (65). Furthermore, SFRP2 may inhibit the 
survival and metastasis of NScLc cells via the Wnt/β-catenin 
signalling pathway (66). Zeng et al (67) reported that SFRP2 
expression was downregulated in choriocarcinoma, and low 
SFRP2 expression induced tumour migration and invasion 
via Wnt/β-catenin signalling. cheng et al observed the same 
phenomena in gastric cancer, in which SFRP2 expression 
was decreased in tumour tissues compared with in adjacent 
non-cancer tissues (68). Additionally, Perry et al (69) revealed 
that SFRP2 expression was lower in prostate cancer tissues 
compared with in normal tissues (P<0.01). Moreover, it has 
been demonstrated that increasing the expression levels of 
SFRP2 can inhibit cancer cell proliferation and lead to cell 
apoptosis in vivo (68).
The methylation of SFRP2 serves an important role in 
tumour invasion and metastasis. Methylation of gene promoter 
regions, mainly located in cpG islands, is a common feature in 
human cancer, where it typically leads to epigenetic silencing 
of tumour suppressor genes (70). SFRP2 is often methylated 
in several types of human cancer, such as melanoma, gastric 
carcinoma, colorectal, liver and lung cancer (63,71-73). In 
Figure 2. SFRP-2 in the Wnt/β-catenin signalling pathway in cancer. (A) Wnt binding to Frizzled/LRP5/6 induces dvl3 accumulation, which inhibits the 
complex of β-catenin, Axin, APc and GSK-3β. This leads to an increase of cytoplasmic β-catenin, which then translocates to the nucleus to interact with 
TcF/LEF family of transcription factors that contribute to cell survival, proliferation and osteoblastic differentiation. SFRP-2 as a competitive receptor of 
Wnt may regulate the Wnt/β-catenin signalling pathway to inhibit cell proliferation and survival, and lead to apoptosis (63,64). (B) SFRP-2 derived from 
aged fibroblasts may inhibit β-catenin and MITF signalling, resulting in a decrease of AEP1 that makes melanoma cells more sensitive to oxidative stress 
and resistant to BRAF inhibitors (74). The figure was prepared utilising templates obtained from www.proteinlounge.com. SFRP‑2, secreted frizzled‑related 
protein 2; LRP5/6, lipoprotein receptor-related protein 5/6; dvl3, dishevelled 3; APc, adenomatosis polyposis coli; GSK-3β, glycogen synthase kinase-3β; 
TcF/LEF, T-cell factor/lymphoid enhancer factor; MITF, microphthalmia-associated transcription factor; AEP1, apurinic/apyrimidinic endonuclease 1.
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an analysis of SFRP2, which included 10 studies, 6 studies 
compared 936 patients with cRc and 794 normal colonic 
mucosa, and 763 patients with cRc and 487 benign mucosal 
lesions. The data demonstrated that SFRP2 methylation in 
cRc was higher than in normal colonic mucosa and benign 
mucosal lesions [odds ratio (OR)=31.38 and P<0.001, and 
OR=4.83 and P<0.001, respectively] (74), indicating that 
SFRP2 methylation may be used as a non-invasive biomarker 
for the diagnosis of cRc. Zhang et al (65) indicated that, 
compared with in normal lung tissues, SFRP2 mRNA expres-
sion was significantly decreased in NSCLC tissues, while the 
methylation of the SFRP2 gene displayed the opposite trend. 
In NScLc cell lines, the demethylation of the SFRP2 gene 
aided in the restoration of SFRP2 expression at the RNA and 
protein levels (65). Therefore, tumour cell invasion may be 
inhibited by the stimulation of SFRP2 (65). It is reported that 
the demethylation of the SFRP2 gene appeared to inhibit two 
key factors, zinc finger E‑box binding homeobox 1 (ZEB1) 
and MMP9 (65). ZEB1 is a promoter involved in EMT, while 
MMP9 is an important MMP family member that leads to 
the degradation of the basement membrane, which results 
in tumour metastasis (65). SFRP2 may therefore suppress 
NScLc invasion by inhibiting ZEB1 and MMP9, and SFRP2 
methylation may promote NScLc invasion (65).
Numerous studies have indicated that SFRP2 acts as an 
anti-oncogene (65,66,68-70); however, other studies have 
suggested the opposite and that it serves as an oncogene to 
promote carcinoma development and progression (63,75-77). 
In breast cancer, SFRP2 expression is upregulated in canine 
mammary gland tumours compared with in normal tissues (78). 
Lee et al (77) indicated that SFRP2 inhibited canine mammary 
gland tumour UV- induced apoptosis via activation of the 
NF-κB signalling pathway or by suppressing the JNK signal-
ling pathway. Additionally, SFRP2 serves a role in leading cell 
adhesion and anti-apoptotic functions by integrating with the 
fibronectin‑integrin protein complex in mammary tumours (75). 
Furthermore, SFRP2 was proposed to lead to tumour growth in 
glioma and renal cancer via activation of canonical Wnt signal-
ling, or to promote angiogenesis through calcineurin/NFAT 
in breast cancer (76). Data suggests that as dermal fibroblasts 
grow old, SFRP2 expression increases as an antagonist of the 
Wnt signalling pathway to drive melanoma cell metastasis (79). 
SFRP2 inhibits β-catenin and microphthalmia-associated 
transcription factor signalling, which is a main regulator of 
melanoma metabolism; this in turn decreases the redox regu-
lator apurinic/apyrimidinic endonuclease 1, which is involved 
in repairing oxidative-based damage, makes melanoma cells 
more sensitive to oxidative stress and drives resistance to 
BRAF inhibitors, which are an effective treatment of metastatic 
melanoma (79) (Fig. 2B). In elderly patients, the TME is more 
likely to activate signalling pathways that drive more aggressive 
melanoma cell behaviour (79). It has previously been reported 
that downregulating SFRP2 results in a decrease of breast 
cancer tumour volume to 46% compared with control tissues in 
mice (80). A similar trend was observed in lung cancer, where 
overexpression of SFRP2 in the NScLc A549 cell line promoted 
lung cancer cell proliferation (81). After downregulating 
SFRP2, both cdK4 and cyclin d1 mRNA and protein expres-
sion was downregulated, and cell proliferation was suppressed 
at the G1 phase (81). considering that when cyclin d1 binds to 
its activator cdK4, it enables the cell cycle G1 checkpoint to 
continue, previous data suggests that SFRP2 may serve a role 
in enhancing lung cancer cell proliferation, invasion and migra-
tion (81). Additionally, Liu et al (63) revealed that overexpression 
of SFRP2 in lung cancer may promote tumour diffusion and 
availability of Wnt proteins, resulting in activation of canonical 
Wnt signalling and tumorigenesis.
Accumulating studies have demonstrated that SFRP2 
regulation is associated with Wnt signalling activity and 
tumour progression, including lung cancer, choriocarci-
noma, gastric cancer, prostate cancer, colorectal cancer and 
melanoma (66-69,71,74). SFRP2 has the potential to act as a 
methylation biomarker for the diagnosis of NScLc (72). It 
functions as an oncogene or anti-oncogene in numerous types 
of cancer, and whether it acts as an antagonist or agonist in Wnt 
signalling remains controversial. Regarding the therapeutic 
aspects, due to the inhibitory functions of SFRP2 observed in the 
majority of studies (65,66,68-70), SFRP2-like molecules or drug 
inhibitors should be explored to target tumour cells and inhibit 
Wnt signalling. XAV939, a Wnt inhibitor, has been demonstrated 
to reverse the EMT phenotype and stemness markers, resulting 
in the inhibition of migratory and invasive abilities in choriocar-
cinoma (67). Moreover, due to the role of SFRP2 methylation 
in promoting tumour progression, drugs that reverse or prevent 
this methylation may be helpful for tumour therapy. For example, 
5-Aza-2'-deoxycytidine is able to cause promoter demethylation 
of SFRP2 and has been demonstrated to inhibit tumour migra-
tion and invasion in choriocarcinoma (67). Similarly, in addition 
to agents that inhibit Wnt signalling and activation of the SFRP2 
gene, therapies that activate silenced genes, such as SFRP2, 
epigenetically may be of interest (82). dNA methyltransferases 
(dNMTs) contribute to the epigenetic regulation, and novel 
drugs targeting DNMTs are the subjects of scientific research in 
ongoing clinical trials in different types of cancer (63).
6. Outlook and future perspectives
For several decades, it was considered that the process of tumour 
development was associated with genetic alterations. There is 
now growing recognition that the TME serves an essential role 
in the process of cancer development. SdFs, which are derived 
from stromal cells, have an impact in tumour-stroma networks 
in cancer. SDF‑1 has been the subject of most scientific research 
and is involved in the progression of various types of cancer and 
stages, including tumorigenesis, metastasis and survival. SdF-2 
and SdF2L1 are ER-resident proteins associated with ER stress. 
SdF2L1 expression is upregulated by ER stress and SdF-2 is 
constitutively expressed. They may function as negative regula-
tors in cancer through activation of the ER stress to balance the 
cellular environment. It has been demonstrated that cancer cells 
may overcome this mechanism, preventing ER stress-induced 
apoptosis (83). Additionally, it has been demonstrated that SdF-2 
can promote acquisition of OXA resistance via enhancing the 
ER stress to avoid OXA-induced stress (42). These results make 
it difficult to understand the role of SDF‑2/SDF2L1 in cancer 
and therefore future work is required to identify and fully estab-
lish the function of SdF-2/SdF2L1 in tumour development, ER 
stress and drug resistance. This elucidation may lead to potential 
therapeutic targets for novel cancer treatments. However, no 
drug or SdF-2-like therapeutics have currently been developed 
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to target SdF-2 for cancer treatment. The splicing isoforms of 
SdF-4 (cab45) may regulate cancer cell mobility, proliferation 
and migration through various mechanisms, including by regu-
lating EMT, MMPs and EcM, but the underlying molecular 
mechanisms surrounding this regulation remain unclear. SdF-4 
appears to have promise as a therapeutic target for the treat-
ment of cancer, but further studies are required to fully explore 
the associated mechanisms. Based on the majority of previous 
studies (65,66,68-70), SFRP2 functions as a negative regulator 
in tumour growth and metastasis in a number of types of cancer; 
however, there are contrasting results. Overall, the specific role 
of SFRP2 in cancer remains unclear. The function of SFRP2 
may be associated with different signalling pathways, different 
stages of tumour progression, human age and different types of 
tumour. Defining the exact function of SFRP2 in different types 
of cancers requires to be further elucidated. If this can be clari-
fied, SFRP2 may serve as a potential target for cancer therapy. A 
number of studies have demonstrated that SFRP2 serves a pivotal 
role in the Wnt signalling pathway and cancer (65-67,76,79). 
SFRP2‑like therapeutics or drug inhibitors warrant scientific 
attention for their capacity to target tumour cells and inhibit 
Wnt signalling. Although there is currently no Wnt inhibitor 
used in the clinical setting, there have been increasing thera-
peutic approaches under research, such as promoters of SFRP2 
activation, Wnt inhibitors and dNA methyltransferases. Further 
studies regarding the role of SFRP2 in cancer are required to 
highlight its potential for tumour treatment.
7. Conclusion
Overall, SdFs serve an important role in tumorigenesis and 
tumour progression. SdF-1 is widely known to enhance tumour 
malignant behaviour. SdF-1 analogues or cXcR4 inhibitors 
have been demonstrated to inhibit tumour growth and metas-
tasis. SdF-2 has some potential as a predictive biomarker in 
tumours, but little progress has been made on the development of 
treatments targeting SdF-2. SdF-4 (cab45) has been observed 
to enhance tumour cell mobility, proliferation and metastasis, 
and may therefore serve as a potential target for tumour treat-
ment. However, further studies are required to explore the 
therapeutic potential of targeting cab45. SFRP2 has been 
observed to serve a controversial role in cancer. The majority 
of previous studies suggest that it functions as an antagonist, 
and there have been some molecular therapeutic interventions 
targeting SFRP2 or Wnt signalling under research, which may 
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